Medpace Holdings, Inc. Reports Third Quarter 2026 Results
• Revenue of $716.0 million in the third quarter of 2026 increased 8.5% from revenue of $659.9 million for the comparable prior-year period, representing a backlog conversion rate of 23.8%.
• Net new business awards were $873.4 million in the third quarter of 2026, representing an increase of 10.6% from net new business awards of $789.6 million for the comparable prior-year period.
• Third quarter of 2026 GAAP net income was $137.5 million, or $4.84 per diluted share, versus GAAP net income of $111.1 million, or $3.86 per diluted share, for the comparable prior-year period. Net income margin was 19.2% and 16.8% for the third quarter of 2026 and 2025, respectively.
• EBITDA was $172.1 million for the third quarter of 2026, an increase of 16.0% from EBITDA of $148.4 million for the comparable prior-year period, resulting in an EBITDA margin of 24.0%.
-- Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the third quarter ended September 30, 2026.
Revenue for the three months ended September 30, 2026 increased 8.5% to $716.0 million, compared to $659.9 million for the comparable prior-year period. On a constant currency basis, revenue for the third quarter of 2026 increased 8.6% compared to the third quarter of 2025.
Backlog as of September 30, 2026 increased 5.6% to $3,167.2 million from $3,000.6 million as of September 30, 2025. Net new business awards were $873.4 million, as compared to $789.6 million for the comparable prior-year period.
For the third quarter of 2026, total direct costs were $492.1 million, compared to total direct costs of $463.0 million in the third quarter of 2025. Selling, general and administrative (SG&A) expenses were $51.8 million in the third quarter of 2026, compared to SG&A expenses of $48.1 million in the third quarter of 2025.
GAAP net income for the third quarter of 2026 was $137.5 million, or $4.84 per diluted share, versus GAAP net income of $111.1 million, or $3.86 per diluted share, for the third quarter of 2025. This resulted in a net income margin of 19.2% and 16.8% for the third quarter of 2026 and 2025, respectively.
EBITDA for the third quarter of 2026 increased 16.0% to $172.1 million, or 24.0% of revenue, compared to $148.4 million, or 22.5% of revenue, for the comparable prior-year period. On a constant currency basis, EBITDA for the third quarter of 2026 increased 16.0% from the third quarter of 2025.
A reconciliation of the Company’s non-GAAP financial measures, including EBITDA and EBITDA margin to the corresponding GAAP measures is provided below. 1
Revenue for the nine months ended September 30, 2026 was $2,129.9 million, and increased 16.9% on a reported basis and 16.7% on a constant currency basis from the comparable prior-year period. Year-to-date 2026 GAAP net income was $382.7 million, or $13.37 per diluted share, compared to $316.0 million, or $10.64 per diluted share, for the comparable prior-year period. Year-to-date 2026 EBITDA was $474.9 million, or 22.3% of revenue, and increased 19.5% on a reported basis and 20.4% on a constant currency basis from the comparable prior-year period.
The Company’s Cash and cash equivalents were $705.3 million at September 30, 2026, and the Company generated $216.6 million in cash flow from operating activities during the third quarter of 2026. There were no share repurchases in the third quarter of 2026. As of September 30, 2026, the Company had $527.0 million remaining under its authorized share repurchase program.
Effective October 20, 2026 (“Effective Date”), the Company’s Board of Directors (“Board”) terminated the Company’s current stock repurchase authorization of the Company’s common stock, $0.01 par value (“common stock”) which was set to expire on December 31, 2026. As of the Effective Date, this repurchase authorization had $527.0 million remaining.
Effective as of the Effective Date, the Board approved a new stock repurchase authorization, pursuant to which the Company is authorized to repurchase up to $1.0 billion shares of common stock until December 31, 2028, at the discretion of the Company’s management. Repurchases under this new authorization may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to alternative uses of capital, prevailing market conditions, applicable regulatory requirements, and other considerations. Under the new authorization, any such repurchases may be executed using open market purchases, privately negotiated transactions, transactions in accordance with Rule 10b5-1 of the Exchange Act, or other transactions, and will be funded from cash on hand. The new authorization does not obligate the Company to acquire any minimum amount of common stock and the new authorization may be modified, limited, extended, suspended or terminated by the Board at any time without prior notice.
The Company forecasts 2026 revenue in the range of $2.835 billion to $2.855 billion, representing growth of 12.0% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income for full year 2026 is forecasted in the range of $514.0 million to $524.0 million. Additionally, full year 2026 EBITDA is expected in the range of $638.0 million to $652.0 million. Based on forecasted 2026 revenue of $2.835 billion to $2.855 billion and GAAP net income of $514.0 million to $524.0 million, diluted earnings per share (GAAP) is forecasted in the range of $17.97 to $18.32. This guidance assumes a full year 2026 tax rate of 19.0% to 19.5%, interest income of $22.9 million, foreign exchange rates as of September 30, 2026, and 28.6 million diluted weighted average shares outstanding. This guidance does not include the potential impact of any share repurchases the Company may make pursuant to the share repurchase program after September 30, 2026.
Medpace will host a conference call at 9:00 a.m. ET, Thursday, October 22, 2026, to discuss its third quarter 2026 results.
To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call.
To access the conference call via webcast, visit the “Investors” section of Medpace’s website at medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. A supplemental slide presentation will also be available at the “Investors” section of Medpace’s website prior to the start of the call.
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined 2 operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 6,600 people across 46 countries as of September 30, 2026.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding our forecasted financial results and the effective tax rate used for non-GAAP adjustment purposes. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “guidance,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” “forecast,” “may,” “could,” “likely,” “project,” “goal,” “objective,” “potential,” “range,” “estimate,” “preliminary,” “opportunity,” “outlook,” “trend,” “can,” “might,” “drives,” “hope,” “future,” “predict” and similar expressions, and variations or negatives of these words. However, the absence of these words does not mean that a statement is not forward-looking.
These forward-looking statements are largely based on management’s current expectations and projections about future events and financial trends that we believe may affect, among other things, our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other factors that may cause our financial condition, actual results, performance (including share price performance), or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward- looking statements, including, but not limited to, the following: the potential loss, delay or non-renewal of our contracts, or the non-payment by customers for services we have performed; the failure to convert backlog to revenue at our present or historical conversion rate(s); the failure to maintain or generate new business awards; fluctuation in our results between fiscal quarters and years; the risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases; decreased operating margins due to increased pricing pressure or other factors; our failure to perform our services or operate our business in accordance with contractual requirements, government regulations and ethical considerations; the impact of underpricing our contracts, overrunning our cost estimates or failing to receive approval for or experiencing delays with documentation of change orders; the failure of third parties to provide us critical support services; our failure to increase our market share, grow our business, successfully execute our growth strategies or manage our growth effectively; the impact of a failure to retain key executives or other personnel or recruit qualified personnel; the risks associated with our information systems infrastructure, including potential cybersecurity breaches and other disruptions which could compromise patient information or our information; risks from use of machine learning and generative artificial intelligence (“AI”), including risks from insufficient human oversight of AI or lack of controls and procedures monitoring AI use; adverse results from customer or therapeutic area concentration; the risks associated with doing business internationally, including the effects of tariffs and trade wars; the risks associated with the Foreign Corrupt Practices Act and other anti-corruption laws; future net losses; the impact of changes in tax laws and regulations; our failure to attract suitable investigators and patients to our clinical trials; the liability risks associated with our research and development services, including risks of liability resulting from harm to patients; inadequate insurance coverage for our operations and indemnification obligations; fluctuations in exchange rates; general economic conditions, including inflation, in the markets in which we and our customers operate, including financial market conditions; the impact of unfavorable economic conditions, including conditions caused by the uncertain international economic environment and current and future international conflicts; the impact of a natural disaster or other catastrophic event; negative outsourcing trends in the biopharmaceutical industry and a reduction in aggregate expenditures and research and development budgets; our inability to compete effectively with other CROs; the impact of healthcare reform; the impact of consolidation in the biopharmaceutical industry; our failure to comply with federal, state and foreign healthcare laws; the effect of current and proposed laws and regulations regarding the protection of personal data; our potential involvement in costly intellectual property lawsuits; actions by regulatory authorities or customers to limit the scope of indications related to or withdraw an approved drug, biologic or medical device from the market; and the impact of industry-wide reputational harm to CROs. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make.
These and other factors discussed under the caption “Risk Factors” in Item 1A, Part I of our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. We cannot guarantee that any forward- looking statement will be realized. Achievement of anticipated results is subject to substantial 3 risks, uncertainties and inaccurate assumptions. If known or unknown risks or uncertainties materialize or if underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events, developments or circumstances cause our views to change. These forward- looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Certain financial measures presented in this press release, such as EBITDA and EBITDA margin, are not recognized under generally accepted accounting principles in the United States of America, or U.S. GAAP. Management uses EBITDA and EBITDA margin or comparable metrics as a measurement used in evaluating our operating performance on a consistent basis, as a consideration to assess incentive compensation for our employees, for planning purposes, including the preparation of our internal annual operating budget, and to evaluate the performance and effectiveness of our operational strategies.
EBITDA and EBITDA margin have important limitations as analytical tools and you should not consider them in isolation, or as a substitute for, analysis of our results as reported under U.S. GAAP. See the condensed consolidated financial statements included elsewhere in this release for our U.S. GAAP results. Additionally, for reconciliations of EBITDA and EBITDA margin to our closest reported U.S. GAAP measures, refer to the appendix of this press release.
We believe that EBITDA and EBITDA margin are useful to provide additional information to investors about certain material non-cash and non-recurring items. While we believe these financial measures are commonly used by investors to evaluate our performance and that of our competitors, because not all companies use identical calculations, this presentation of EBITDA and EBITDA margin may not be comparable to other similarly titled measures of other companies and should not be considered as an alternative to performance measures derived in accordance with U.S. GAAP. EBITDA is calculated as net income attributable to Medpace Holdings, Inc. before income tax expense, interest income, net, depreciation and amortization. EBITDA margin is calculated by dividing EBITDA by Revenue, net for each period. Our presentation of EBITDA and EBITDA margin should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. 4
(Amounts in thousands, except share September 30, December 31, amounts) As of 2026 2025 ────────────────────────────────────────────────────────────────────────────── ASSETS Current assets: Cash and cash equivalents $ 705,315 $ 497,049 Accounts receivable and unbilled, 447,642 402,078 net Prepaid expenses and other current 92,043 90,497 assets Total current assets 1,245,000 989,624 Property and equipment, net 175,004 131,055 Operating lease right-of-use 152,549 117,815 assets Goodwill 662,396 662,396 Intangible assets, net 32,955 33,420 Deferred income taxes 3,272 19,223 Other assets 31,419 21,939 Total assets $ 2,302,595 $ 1,975,472 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Accounts payable $ 43,682 $ 28,142 Accrued expenses 443,331 408,382 Advanced billings 961,855 854,390 Other current liabilities 47,229 52,834 Total current liabilities 1,496,097 1,343,748 Operating lease liabilities 146,041 113,643 Deferred income tax liability 13,657 1,355 Other long-term liabilities 61,861 57,655 Total liabilities 1,717,656 1,516,401 Commitments and contingencies Shareholders’ equity: Preferred stock - $0.01 par-value; 5,000,000 shares authorized; no shares — — issued and outstanding at September 30, 2026 and December 31, 2025 Common stock - $0.01 par-value; 250,000,000 shares authorized at September 30, 2026 and December 31, 2025; 27,966,686 and 28,370,780 280 284 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively Treasury stock - 69,593 and 69,623 -12,151 -12,156 shares at September 30, 2026 and December 31, 2025, respectively Additional paid-in capital 978,282 935,830 Accumulated deficit -373,573 -459,981 Accumulated other comprehensive -7,899 -4,906 loss Total shareholders’ equity 584,939 459,071 Total liabilities and shareholders’ $ 2,302,595 $ 1,975,472 equity
(Amounts in thousands) Nine Months Ended CASH FLOWS FROM OPERATING September 30, ACTIVITIES: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 382,692 $ 315,990 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation 19,731 20,284 Amortization 465 709 Stock-based compensation 16,870 29,166 expense Noncash lease expense 18,063 17,329 Deferred income tax 28,220 63,366 provision Other 669 -433 Changes in assets and liabilities: Accounts receivable and -45,148 -77,119 unbilled, net Prepaid expenses and other current -2,576 -15,607 assets Accounts payable 1,469 1,296 Accrued expenses 36,101 57,521 Advanced billings 107,465 123,743 Lease liabilities -17,807 -18,131 Other assets and -15,818 2,457 liabilities, net Net cash provided by operating 530,396 520,571 activities CASH FLOWS FROM INVESTING ACTIVITIES: Property and equipment -50,886 -26,820 expenditures Other 115 153 Net cash used in investing -50,771 -26,667 activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from stock option 25,590 34,272 exercises Repurchases of common stock -294,764 -917,389 Net cash used in financing -269,174 -883,117 activities EFFECT OF EXCHANGE RATES ON CASH AND -2,185 5,128 CASH EQUIVALENTS INCREASE (DECREASE) IN CASH AND CASH 208,266 -384,085 EQUIVALENTS CASH AND CASH EQUIVALENTS — Beginning of 497,049 669,436 period CASH AND CASH EQUIVALENTS — End of $ 705,315 $ 285,351 period
Full text with the tables
Exhibit 99.1
Investor Contact:
David Ruhe
283-227-6472
[email protected]
FOR IMMEDIATE RELEASE
Media Contact:
Michael Maley
283-227-6367
[email protected]
Medpace Holdings, Inc. Reports Third Quarter 2026 Results
• Revenue of $716.0 million in the third quarter of 2026 increased 8.5% from
revenue of $659.9 million for the comparable prior-year period, representing a
backlog conversion rate of 23.8%.
• Net new business awards were $873.4 million in the third quarter of 2026,
representing an increase of 10.6% from net new business awards of $789.6 million
for the comparable prior-year period.
• Third quarter of 2026 GAAP net income was $137.5 million, or $4.84 per diluted
share, versus GAAP net income of $111.1 million, or $3.86 per diluted share, for
the comparable prior-year period. Net income margin was 19.2% and 16.8% for the
third quarter of 2026 and 2025, respectively.
• EBITDA was $172.1 million for the third quarter of 2026, an increase of 16.0%
from EBITDA of $148.4 million for the comparable prior-year period, resulting in
an EBITDA margin of 24.0%.
CINCINNATI, OHIO, October 21, 2026
-- Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial
results for the third quarter ended September 30, 2026.
Third Quarter 2026 Financial Results
Revenue for the three months ended September 30, 2026 increased 8.5% to $716.0
million, compared to $659.9 million for the comparable prior-year period. On a
constant currency basis, revenue for the third quarter of 2026 increased 8.6%
compared to the third quarter of 2025.
Backlog as of September 30, 2026 increased 5.6% to $3,167.2 million from
$3,000.6 million as of September 30, 2025. Net new business awards were $873.4
million, as compared to $789.6 million for the comparable prior-year period.
For the third quarter of 2026, total direct costs were $492.1 million, compared
to total direct costs of $463.0 million in the third quarter of 2025. Selling,
general and administrative (SG&A) expenses were $51.8 million in the third
quarter of 2026, compared to SG&A expenses of $48.1 million in the third quarter
of 2025.
GAAP net income for the third quarter of 2026 was $137.5 million, or $4.84 per
diluted share, versus GAAP net income of $111.1 million, or $3.86 per diluted
share, for the third quarter of 2025. This resulted in a net income margin of
19.2% and 16.8% for the third quarter of 2026 and 2025, respectively.
EBITDA for the third quarter of 2026 increased 16.0% to $172.1 million, or 24.0%
of revenue, compared to $148.4 million, or 22.5% of revenue, for the comparable
prior-year period. On a constant currency basis, EBITDA for the third quarter of
2026 increased 16.0% from the third quarter of 2025.
A reconciliation of the Company’s non-GAAP financial measures, including EBITDA
and EBITDA margin to the corresponding GAAP measures is provided below.
1
Year-to-Date 2026 Financial Results
Revenue for the nine months ended September 30, 2026 was $2,129.9 million, and
increased 16.9% on a reported basis and 16.7% on a constant currency basis from
the comparable prior-year period. Year-to-date 2026 GAAP net income was $382.7
million, or $13.37 per diluted share, compared to $316.0 million, or $10.64 per
diluted share, for the comparable prior-year period. Year-to-date 2026 EBITDA
was $474.9 million, or 22.3% of revenue, and increased 19.5% on a reported basis
and 20.4% on a constant currency basis from the comparable prior-year period.
Balance Sheet and Liquidity
The Company’s Cash and cash equivalents were $705.3 million at September 30,
2026, and the Company generated $216.6 million in cash flow from operating
activities during the third quarter of 2026. There were no share repurchases in
the third quarter of 2026. As of September 30, 2026, the Company had $527.0
million remaining under its authorized share repurchase program.
Effective October 20, 2026 (“Effective Date”), the Company’s Board of Directors
(“Board”) terminated the Company’s current stock repurchase authorization of the
Company’s common stock, $0.01 par value (“common stock”) which was set to expire
on December 31, 2026. As of the Effective Date, this repurchase authorization
had $527.0 million remaining.
Effective as of the Effective Date, the Board approved a new stock repurchase
authorization, pursuant to which the Company is authorized to repurchase up to
$1.0 billion shares of common stock until December 31, 2028, at the discretion
of the Company’s management. Repurchases under this new authorization may be
made, from time to time, in amounts and at prices the Company deems appropriate,
subject to alternative uses of capital, prevailing market conditions, applicable
regulatory requirements, and other considerations. Under the new authorization,
any such repurchases may be executed using open market purchases, privately
negotiated transactions, transactions in accordance with Rule 10b5-1 of the
Exchange Act, or other transactions, and will be funded from cash on hand. The
new authorization does not obligate the Company to acquire any minimum amount of
common stock and the new authorization may be modified, limited, extended,
suspended or terminated by the Board at any time without prior notice.
2026 Financial Guidance
The Company forecasts 2026 revenue in the range of $2.835 billion to $2.855
billion, representing growth of 12.0% to 12.8% over 2025 revenue of $2.530
billion. GAAP net income for full year 2026 is forecasted in the range of $514.0
million to $524.0 million. Additionally, full year 2026 EBITDA is expected in
the range of $638.0 million to $652.0 million. Based on forecasted 2026 revenue
of $2.835 billion to $2.855 billion and GAAP net income of $514.0 million to
$524.0 million, diluted earnings per share (GAAP) is forecasted in the range of
$17.97 to $18.32. This guidance assumes a full year 2026 tax rate of 19.0% to
19.5%, interest income of $22.9 million, foreign exchange rates as of September
30, 2026, and 28.6 million diluted weighted average shares outstanding. This
guidance does not include the potential impact of any share repurchases the
Company may make pursuant to the share repurchase program after September 30,
2026.
Conference Call Details
Medpace will host a conference call at 9:00 a.m. ET, Thursday, October 22, 2026,
to discuss its third quarter 2026 results.
To participate in the conference call, interested parties must register in
advance by clicking on this link. While it is not required, it is recommended
you join 10 minutes prior to the event start. Upon registration, all telephone
participants will receive a confirmation email detailing how to join the
conference call, including the dial-in number along with a unique PIN that can
be used to access the call.
To access the conference call via webcast, visit the “Investors” section of
Medpace’s website at medpace.com. The webcast replay of the call will be
available at the same site approximately one hour after the end of the call. A
supplemental slide presentation will also be available at the “Investors”
section of Medpace’s website prior to the start of the call.
About Medpace
Medpace is a scientifically-driven, global, full-service clinical contract
research organization (CRO) providing Phase I-IV clinical development services
to the biotechnology, pharmaceutical and medical device industries. Medpace’s
mission is to accelerate the global development of safe and effective medical
therapeutics through its high-science and disciplined
2
operating approach that leverages regulatory and therapeutic expertise across
all major areas including oncology, cardiology, metabolic disease,
endocrinology, central nervous system and anti-viral and anti-infective.
Headquartered in Cincinnati, Ohio, Medpace employs approximately 6,600 people
across 46 countries as of September 30, 2026.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements contained in
this press release that do not relate to matters of historical fact should be
considered forward-looking statements, including without limitation, statements
regarding our forecasted financial results and the effective tax rate used for
non-GAAP adjustment purposes. In this context, forward-looking statements often
address expected future business and financial performance and financial
condition, and often contain words such as “guidance,” “expect,” “anticipate,”
“intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,”
“forecast,” “may,” “could,” “likely,” “project,” “goal,” “objective,”
“potential,” “range,” “estimate,” “preliminary,” “opportunity,” “outlook,”
“trend,” “can,” “might,” “drives,” “hope,” “future,” “predict” and similar
expressions, and variations or negatives of these words. However, the absence of
these words does not mean that a statement is not forward-looking.
These forward-looking statements are largely based on management’s current
expectations and projections about future events and financial trends that we
believe may affect, among other things, our financial condition, results of
operations, business strategy, short-term and long-term business operations and
objectives, and financial needs. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and other factors
that may cause our financial condition, actual results, performance (including
share price performance), or achievements to be materially different from any
future results, performance or achievements expressed or implied by the forward-
looking statements, including, but not limited to, the following: the potential
loss, delay or non-renewal of our contracts, or the non-payment by customers for
services we have performed; the failure to convert backlog to revenue at our
present or historical conversion rate(s); the failure to maintain or generate
new business awards; fluctuation in our results between fiscal quarters and
years; the risks and uncertainties related to disruptions to or reductions in
business operations or prospects due to pandemics, epidemics, widespread health
emergencies, or outbreaks of infectious diseases; decreased operating margins
due to increased pricing pressure or other factors; our failure to perform our
services or operate our business in accordance with contractual requirements,
government regulations and ethical considerations; the impact of underpricing
our contracts, overrunning our cost estimates or failing to receive approval for
or experiencing delays with documentation of change orders; the failure of third
parties to provide us critical support services; our failure to increase our
market share, grow our business, successfully execute our growth strategies or
manage our growth effectively; the impact of a failure to retain key executives
or other personnel or recruit qualified personnel; the risks associated with our
information systems infrastructure, including potential cybersecurity breaches
and other disruptions which could compromise patient information or our
information; risks from use of machine learning and generative artificial
intelligence (“AI”), including risks from insufficient human oversight of AI or
lack of controls and procedures monitoring AI use; adverse results from customer
or therapeutic area concentration; the risks associated with doing business
internationally, including the effects of tariffs and trade wars; the risks
associated with the Foreign Corrupt Practices Act and other anti-corruption
laws; future net losses; the impact of changes in tax laws and regulations; our
failure to attract suitable investigators and patients to our clinical trials;
the liability risks associated with our research and development services,
including risks of liability resulting from harm to patients; inadequate
insurance coverage for our operations and indemnification obligations;
fluctuations in exchange rates; general economic conditions, including
inflation, in the markets in which we and our customers operate, including
financial market conditions; the impact of unfavorable economic conditions,
including conditions caused by the uncertain international economic environment
and current and future international conflicts; the impact of a natural disaster
or other catastrophic event; negative outsourcing trends in the
biopharmaceutical industry and a reduction in aggregate expenditures and
research and development budgets; our inability to compete effectively with
other CROs; the impact of healthcare reform; the impact of consolidation in the
biopharmaceutical industry; our failure to comply with federal, state and
foreign healthcare laws; the effect of current and proposed laws and regulations
regarding the protection of personal data; our potential involvement in costly
intellectual property lawsuits; actions by regulatory authorities or customers
to limit the scope of indications related to or withdraw an approved drug,
biologic or medical device from the market; and the impact of industry-wide
reputational harm to CROs. Moreover, we operate in a very competitive and
rapidly changing environment in which new risks emerge from time to time. It is
not possible for our management to predict all risks, nor can we assess the
impact of all factors on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ materially from those
contained in any forward-looking statements we may make.
These and other factors discussed under the caption “Risk Factors” in Item 1A,
Part I of our Annual Report on Form 10-K filed with the Securities and Exchange
Commission, or SEC, and our other reports filed with the SEC could cause actual
results to differ materially from those indicated by the forward-looking
statements made in this press release. We cannot guarantee that any forward-
looking statement will be realized. Achievement of anticipated results is
subject to substantial
3
risks, uncertainties and inaccurate assumptions. If known or unknown risks or
uncertainties materialize or if underlying assumptions prove inaccurate, actual
results could vary materially from past results and those anticipated, estimated
or projected. These factors should not be construed as exhaustive and should be
read in conjunction with the other cautionary statements that are included in
this release and in our filings with the SEC. Any such forward-looking
statements represent management’s estimates as of the date of this press
release. While we may elect to update such forward-looking statements at some
point in the future, we disclaim any obligation to do so, even if subsequent
events, developments or circumstances cause our views to change. These forward-
looking statements should not be relied upon as representing our views as of any
date subsequent to the date of this press release.
Non-GAAP Financial Measures
Certain financial measures presented in this press release, such as EBITDA and
EBITDA margin, are not recognized under generally accepted accounting principles
in the United States of America, or U.S. GAAP. Management uses EBITDA and EBITDA
margin or comparable metrics as a measurement used in evaluating our operating
performance on a consistent basis, as a consideration to assess incentive
compensation for our employees, for planning purposes, including the preparation
of our internal annual operating budget, and to evaluate the performance and
effectiveness of our operational strategies.
EBITDA and EBITDA margin have important limitations as analytical tools and you
should not consider them in isolation, or as a substitute for, analysis of our
results as reported under U.S. GAAP. See the condensed consolidated financial
statements included elsewhere in this release for our U.S. GAAP results.
Additionally, for reconciliations of EBITDA and EBITDA margin to our closest
reported U.S. GAAP measures, refer to the appendix of this press release.
We believe that EBITDA and EBITDA margin are useful to provide additional
information to investors about certain material non-cash and non-recurring
items. While we believe these financial measures are commonly used by investors
to evaluate our performance and that of our competitors, because not all
companies use identical calculations, this presentation of EBITDA and EBITDA
margin may not be comparable to other similarly titled measures of other
companies and should not be considered as an alternative to performance measures
derived in accordance with U.S. GAAP. EBITDA is calculated as net income
attributable to Medpace Holdings, Inc. before income tax expense, interest
income, net, depreciation and amortization. EBITDA margin is calculated by
dividing EBITDA by Revenue, net for each period. Our presentation of EBITDA and
EBITDA margin should not be construed as an inference that our future results
will be unaffected by unusual or non-recurring items.
4
MEDPACE HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(A…
in
th… Th… Ni…
ex… Mo… Mo…
per En… En…
sh… Se… Se…
am… 20… 30, 20… 2026 30, 20…
──────────────────────────────────────────────────────────────────────────────
R… $ 71… $ 65… $ 2,… $ 1,8…
n…
O…
e…
D…
s…
c…
e… 20… 18… 60… 549…
d…
a…
a…
R…
o… 28… 27… 90… 716…
e…
T…
d… 49… 46… 1,… 1,2…
c…
S…
g… 51… 48… 14… 152…
a…
a…
D… 6,… 6,… 19… 20,…
A… 155 236 465 709
T…
o… 55… 51… 1,… 1,4…
e…
I…
f… 16… 14… 45… 381…
o…
O…
i…
n…
M…
i… 17 -4… 841 -5,…
(…
n…
I…
i… 5,… 1,… 15… 9,0…
n…
T…
o… 5,… 1,… 16… 3,8…
i…
n…
I…
b… 17… 14… 47… 385…
i…
t…
I…
t… 33… 31… 87… 69,…
p…
N… $ 13… $ 11… $ 38… $ 315…
i…
N…
i…
p…
s…
a…
to
c…
s…
B… $ 4.… $ 3.… $ 13… $ 10.…
D… $ 4.… $ 3.… $ 13… $ 10.…
W…
a…
c…
s…
o…
B… 27… 28… 28,… 29…
D… 28… 28… 28,… 29…
5
MEDPACE HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(Amounts in thousands, except
share September 30, December 31,
amounts) As of 2026 2025
──────────────────────────────────────────────────────────────────────────────
ASSETS
Current assets:
Cash and cash equivalents $ 705,315 $ 497,049
Accounts receivable and unbilled, 447,642 402,078
net
Prepaid expenses and other
current 92,043 90,497
assets
Total current assets 1,245,000 989,624
Property and equipment, net 175,004 131,055
Operating lease right-of-use 152,549 117,815
assets
Goodwill 662,396 662,396
Intangible assets, net 32,955 33,420
Deferred income taxes 3,272 19,223
Other assets 31,419 21,939
Total assets $ 2,302,595 $ 1,975,472
LIABILITIES AND SHAREHOLDERS’
EQUITY
Current liabilities:
Accounts payable $ 43,682 $ 28,142
Accrued expenses 443,331 408,382
Advanced billings 961,855 854,390
Other current liabilities 47,229 52,834
Total current liabilities 1,496,097 1,343,748
Operating lease liabilities 146,041 113,643
Deferred income tax liability 13,657 1,355
Other long-term liabilities 61,861 57,655
Total liabilities 1,717,656 1,516,401
Commitments and contingencies
Shareholders’ equity:
Preferred stock - $0.01
par-value;
5,000,000 shares authorized; no
shares — —
issued and outstanding at
September 30,
2026 and December 31, 2025
Common stock - $0.01 par-value;
250,000,000 shares authorized at
September 30, 2026 and December
31,
2025; 27,966,686 and 28,370,780 280 284
shares
issued and outstanding at
September 30,
2026 and December 31, 2025,
respectively
Treasury stock - 69,593 and
69,623 -12,151 -12,156
shares at September 30, 2026 and
December 31, 2025, respectively
Additional paid-in capital 978,282 935,830
Accumulated deficit -373,573 -459,981
Accumulated other comprehensive -7,899 -4,906
loss
Total shareholders’ equity 584,939 459,071
Total liabilities and
shareholders’ $ 2,302,595 $ 1,975,472
equity
6
MEDPACE HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(Amounts in thousands) Nine Months Ended
CASH FLOWS FROM OPERATING September 30,
ACTIVITIES: 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 382,692 $ 315,990
Adjustments to reconcile
net income to
net cash provided by
operating
activities:
Depreciation 19,731 20,284
Amortization 465 709
Stock-based compensation 16,870 29,166
expense
Noncash lease expense 18,063 17,329
Deferred income tax 28,220 63,366
provision
Other 669 -433
Changes in assets and
liabilities:
Accounts receivable and -45,148 -77,119
unbilled, net
Prepaid expenses and other
current -2,576 -15,607
assets
Accounts payable 1,469 1,296
Accrued expenses 36,101 57,521
Advanced billings 107,465 123,743
Lease liabilities -17,807 -18,131
Other assets and -15,818 2,457
liabilities, net
Net cash provided by
operating 530,396 520,571
activities
CASH FLOWS FROM INVESTING
ACTIVITIES:
Property and equipment -50,886 -26,820
expenditures
Other 115 153
Net cash used in investing -50,771 -26,667
activities
CASH FLOWS FROM FINANCING
ACTIVITIES:
Proceeds from stock option 25,590 34,272
exercises
Repurchases of common stock -294,764 -917,389
Net cash used in financing -269,174 -883,117
activities
EFFECT OF EXCHANGE RATES ON
CASH AND -2,185 5,128
CASH EQUIVALENTS
INCREASE (DECREASE) IN CASH
AND CASH 208,266 -384,085
EQUIVALENTS
CASH AND CASH EQUIVALENTS —
Beginning of 497,049 669,436
period
CASH AND CASH EQUIVALENTS —
End of $ 705,315 $ 285,351
period
7
MEDPACE HOLDINGS, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)
(Am…
in
tho…
exc…
per…
REC…
OF Three Nine
GAAP Mont… Mon…
NET Ended End…
INC… Sept… Sep…
TO 30, 30,
EBI… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net
inc… $ 137,… $ 111,… $ 382,… $ 315…
(GA…
Int…
inc… -5,3… -1,5… -15,… -9,…
net
Inc…
tax 33,4… 31,7… 87,4… 69,…
pro…
Dep… 6,425 6,813 19,7… 20,…
Amo… 155 236 465 709
EBI… $ 172,… $ 148,… $ 474,… $ 397…
(No…
Net
inc… 19.2 % 16.8 % 18.0 % 17.3 %
mar…
(GA…
EBI…
mar… 24.0 % 22.5 % 22.3 % 21.8 %
(No…
FY 2026 GUIDANCE RECONCILIATION (UNAUDITED)
(Amoun…
in Net
millio… Forecast income
except 2026 per
per Net diluted
share Income share
amount… Low High Low High
──────────────────────────────────────────────────────────────────────────────
Net
income
and net
income $ 514.0 $ 524.0 $ 17.97 $ 18.32
per
diluted
share
(GAAP)
Income
tax 119.5 123.5
provis…
Intere…
income, -22.9 -22.9
net
Deprec… 26.8 26.8
Amorti… 0.6 0.6
EBITDA $ 638.0 $ 652.0
(Non-G…
8